CONTACT US

Skyepharma is a specialist CDMO

for the development and manufacturing of complex oral solid forms for controlled release applications.

  • Tab-in-tab
  • Multi-layer tablets
  • Enteric capsules

Fully integrated CDMO offering tailor-made solutions

We provide tailor-made solutions to our customers by positioning ourselves as a fully integrated CDMO offering a wide range of premium services.


Our experienced team of specialists works to optimize target product profile and drug development program from early formulation development, scale-up, manufacturing and packaging to regulatory support.

CDMO center of excellence in Development

Formulation development

We have extensive experience in solving complex formulation challenges. Our experts will advise you on the best solution to optimise drug delivery for the benefit to the patients. We could include our range of proprietary technologies to provide modified, pulse or timed release profiles  to solve technological challenges, to provide patient benefits and to offer additional proprietary protection to the product.

Prototyping

We perform rapid and flexible prototyping essays to early characterized powders leading to anticipate potential up scaling issues which lead to save time and money.


Our key differentiators regards our compression simulator (Styl’One Evolution) and low scale equipment which reproduce industrial processes such as wet granulation, compression including tabletting and roller compaction and coating.

Product manufacturing for clinical trial

Once formulation is validated, we use our cGMP facilities to supply product for clinical study. Regulatory support is provided to assist you during clinical phases.

Controlled release technologies

Oral Drug Delivery Technologies

Skyepharma controlled release expertise is the result of years as a leader in drug development and oral drug delivery technologies serving the global pharmaceutical industry. Since it was founded, Skyepharma has had a strong focus on oral drug delivery, solving the many challenges of delivering the right dose of a drug to the right part of the gastrointestinal system for absorption at the right time and at the appropriate rate to achieve the desired therapeutic effect.

Oral Patented Technologies

3 patented pharmaceutical technologies: Geomatrix®, Geoclock®,and Soctec®. These platforms allow us to build controlled release formulations to adapt to patient dosing schedules or adjust API intake. These proprietary technologies allow us to better manage side effects

Brand new packaging lines - Serialization & aggregation: 

Since 2018, oral dosage CDMO Skyepharma radically updated and expanded its packaging capabilities, opening new packaging lines equipped for serialization and aggregation.  

WE ARE AVAILABLE FOR YOU

CONTACT US

Go to article: Home | Pause for thoughtGo to article: In this issueGo to article: NSFGo to article: ContentsGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: NewsGo to article: BaxterGo to article: Covid-19 executive briefing by GlobalDataGo to article: ELPRO Monitoring SolutionsGo to article: Abivax’s ABX464 enticing in theory for Covid-19 but mechanism, trial design issues belie potential for successGo to article: Abiomed’s Impella receives FDA Emergency Use Authorization during Covid-19Go to article: FargoGo to article: Disruptions to global oncology trials have fallen to a three-month lowGo to article: MimotopesGo to article: AstraZeneca/Oxford University and CanSino publish promising Covid-19 vaccine cliGo to article: Biotech IPO valuation relies on data to enter capital markets during Covid-19 paGo to article: Nelson LabsGo to article: The pharma industry briefingGo to article: Pfeiffer VacuumGo to article: A century of cultures: celebrating the world’s oldest lab culture collectionGo to article: SkyepharmaGo to article: Gut feeling: exploring the therapeutic potential of the gut-brain axisGo to article: OptelGo to article: Crabby concoctions: why pharma’s thirst for crustacean blood is up for debateGo to article: Air FranceGo to article: Debunking myths about puberty blockers for transgender childrenGo to article: MicronovaGo to article: Hiring from home: pharma recruitment in the age of Covid-19 Go to article: Nipro PharmapackagingGo to article: Q&A: breaking new ground in pharma packaging with HoneywellGo to article: WipotecGo to article: Treatment-resistant rare diseases: exploring landmark drug approvals in 2020Go to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Modernising pharma patents: can AI be an inventor?Go to article: ILC Dover Go to article: Boosting agility to accelerate project timescales Go to article: Scandinavian HealthGo to article: Doing the right thing: the enhanced case for complianceGo to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue